Annexon, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANNX Nasdaq 2836 www.annexonbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Annexon, Inc.

Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year - Jan 13th, 2025 1:00 pm
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones - Jan 10th, 2025 1:00 pm
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 7th, 2025 1:00 pm
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Dec 16th, 2024 9:05 pm
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) - Dec 16th, 2024 12:30 pm
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting - Dec 5th, 2024 1:00 pm
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate. - Nov 19th, 2024 8:00 am
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones - Nov 14th, 2024 1:00 pm
Annexon Biosciences to Present at the Jefferies London Healthcare Conference - Nov 13th, 2024 9:05 pm
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting - Oct 22nd, 2024 12:00 am
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely - Oct 21st, 2024 1:57 pm
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting - Oct 15th, 2024 12:00 pm
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress - Sep 9th, 2024 12:00 pm
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio - Sep 3rd, 2024 12:00 pm
Annexon Biosciences to Participate in Upcoming September Investor Conferences - Aug 29th, 2024 12:00 pm
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones - Aug 12th, 2024 12:00 pm
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? - Aug 6th, 2024 1:40 pm
Annexon Insider Ups Holding During Year - Aug 3rd, 2024 12:20 pm
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Jul 16th, 2024 8:05 pm
Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year? - Jul 15th, 2024 1:40 pm